Retrieve available abstracts of 20 articles: HTML format
Single Articles
May 2025
ROSANU NM, Gervaso L, Cella CA, Fazio N, et al Navigating the clinical challenges of zolbetuximab in patients with claudin
positive advanced gastric cancer.
Eur J Cancer. 2025;224:115521. PubMedAbstract available
March 2025
KAMP D, May AM, Adenis A, Capela A, et al Optimal timing for initiating first-line palliative systemic therapy in
asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi
study.
Eur J Cancer. 2025;218:115278. PubMedAbstract available
SATOH T, Barthelemy P, Nogova L, Honda K, et al Phase 2 study of futibatinib in patients with gastric or gastroesophageal
junction cancer harboring FGFR2 amplifications.
Eur J Cancer. 2025;218:115262. PubMedAbstract available
February 2025
ISHIDA H, Sunakawa Y, Kodera Y, Yoshida K, et al Post-recurrence survival in patients with stage III gastric cancer who received
adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study.
Eur J Cancer. 2025;219:115322. PubMedAbstract available
November 2024
GEERTS JFM, Pape M, Vissers PAJ, Verhoeven RHA, et al Patient access to perioperative chemotherapy with fluorouracil, leucovorin,
oxaliplatin and docetaxel in patients with resectable gastric cancer in the
Netherlands.
Eur J Cancer. 2024;214:115137. PubMedAbstract available
October 2024
FUJITANI K, Kurokawa Y, Wada R, Takeno A, et al Prospective single-arm multicenter interventional study of surgical resection for
liver metastasis from gastric cancer; 3-year overall and recurrence-free
survival.
Eur J Cancer. 2024;213:115080. PubMedAbstract available
SCHIRIZZI A, Donghia R, De Nunzio V, Renna N, et al High levels of autotaxin and lysophosphatidic acid predict poor outcome in
treatment of resectable gastric carcinoma.
Eur J Cancer. 2024;213:115066. PubMedAbstract available
June 2024
KROESE TE, Bronzwaer S, van Rossum PSN, Schoppman SF, et al European clinical practice guidelines for the definition, diagnosis, and
treatment of oligometastatic esophagogastric cancer (OMEC-4).
Eur J Cancer. 2024;204:114062. PubMedAbstract available
May 2024
RAIMONDI A, Kim YW, Kang WK, Langley RE, et al Prognostic and predictive impact of sex in locally advanced microsatellite
instability high gastric or gastroesophageal junction cancer: An individual
patient data pooled analysis of randomized clinical trials.
Eur J Cancer. 2024;203:114043. PubMedAbstract available
April 2024
DIERKS S, Buchholz SM, Konig A, Liersch T, et al Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer:
Reconsidering the 5-FU dosage strategy.
Eur J Cancer. 2024;204:114076. PubMed
January 2024
ZHAO P, Li S, Du X Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric
cancer: A long way to go.
Eur J Cancer. 2024;199:113554. PubMed
VAN DER SLUIS K, Taylor SN, Kodach LL, van Dieren JM, et al Tumor-positive peritoneal cytology in patients with gastric cancer is associated
with poor outcome: A nationwide study.
Eur J Cancer. 2024;199:113541. PubMedAbstract available
December 2023
TAIEB J, Bennouna J, Penault-Llorca F, Basile D, et al Treatment of gastric adenocarcinoma: A rapidly evolving landscape.
Eur J Cancer. 2023;195:113370. PubMedAbstract available
September 2023
AIX PONCE S, Cousin S, Dubos P, Belcaid L, et al Letter re: Hyperprogressive disease during PD-1 blockade in patients with
advanced gastric cancer.
Eur J Cancer. 2023;193:113309. PubMed
MUTI HS, Rocken C, Behrens HM, Loffler CML, et al Deep learning trained on lymph node status predicts outcome from gastric cancer
histopathology: a retrospective multicentric study.
Eur J Cancer. 2023;194:113335. PubMedAbstract available
July 2023
KALFF MC, Dijksterhuis WPM, Wagner AD, Oertelt-Prigione S, et al Sex differences in treatment allocation and survival of potentially curable
gastroesophageal cancer: A population-based study.
Eur J Cancer. 2023;187:114-123. PubMedAbstract available
June 2023
ASPLUND JPU, Mackenzie HA, Markar SR, Lagergren JHF, et al Surgeon proficiency gain and survival after gastrectomy for gastric
adenocarcinoma: A population-based cohort study.
Eur J Cancer. 2023;186:91-97. PubMedAbstract available
JIA K, Chen Y, Xie Y, Chong X, et al Multidimensional immune profiling in Gastric Cancer Multiplex
Immunohistochemistry Atlas from Peking University Cancer Hospital project informs
PD-1/PD-L1 blockade efficacy.
Eur J Cancer. 2023;189:112931. PubMedAbstract available
April 2023
PORTH I, Hirsch D, Ceribas Y, Weidner P, et al Comprehensive biomarker analysis of long-term response to trastuzumab in patients
with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Eur J Cancer. 2023;183:119-130. PubMedAbstract available
February 2023
KAWAKAMI H, Sunakawa Y, Inoue E, Matoba R, et al Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer
patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER
trial.
Eur J Cancer. 2023;184:10-20. PubMedAbstract available